Cargando…

Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin

AIMS/OBJECTIVE: Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Recent studies have demonstrated that podocyte injury is involved in the onset of and progression to renal insufficiency. Here, we describe a novel, highly sensitive ELISA for detecting ur...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, M., Yamagata, K., Tomino, Y., Saito, A., Hirayama, Y., Ogasawara, S., Kurosawa, H., Sekine, S., Yan, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464371/
https://www.ncbi.nlm.nih.gov/pubmed/22854890
http://dx.doi.org/10.1007/s00125-012-2661-7
_version_ 1782245417993371648
author Hara, M.
Yamagata, K.
Tomino, Y.
Saito, A.
Hirayama, Y.
Ogasawara, S.
Kurosawa, H.
Sekine, S.
Yan, K.
author_facet Hara, M.
Yamagata, K.
Tomino, Y.
Saito, A.
Hirayama, Y.
Ogasawara, S.
Kurosawa, H.
Sekine, S.
Yan, K.
author_sort Hara, M.
collection PubMed
description AIMS/OBJECTIVE: Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Recent studies have demonstrated that podocyte injury is involved in the onset of and progression to renal insufficiency. Here, we describe a novel, highly sensitive ELISA for detecting urinary podocalyxin, a glycoconjugate on the podocyte apical surface that indicates podocyte injury, particularly in the early phase of diabetic nephropathy. METHODS: Urine samples from patients with glomerular diseases (n = 142) and type 2 diabetes (n = 71) were used to quantify urinary podocalyxin by ELISA. Urine samples were obtained from 69 healthy controls for whom laboratory data were within normal values. Podocalyxin was detected in urine by immunofluorescence, immunoelectron microscopy and western blotting. RESULTS: Morphologically, urinary podocalyxin was present as a vesicular structure; western blotting showed it as a positive band at 165–170 kDa. Levels of urinary podocalyxin were elevated in patients with various glomerular diseases and patients with diabetes. In patients with diabetes, urinary podocalyxin was higher than the cut-off value in 53.8% patients at the normoalbuminuric stage, 64.7% at the microalbuminuric stage and 66.7% at the macroalbuminuric stage. Positive correlations were observed between urinary podocalyxin levels and HbA(1c), urinary β(2) microglobulin, α(1) microglobulin and urinary N-acetyl-β-d-glucosaminidase, although urinary podocalyxin levels were not correlated with other laboratory markers such as blood pressure, lipid level, serum creatinine, estimated GFR or proteinuria. CONCLUSIONS/INTERPRETATION: Urinary podocalyxin may be a useful biomarker for detecting early podocyte injury in patients with diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-012-2661-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-3464371
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-34643712012-10-05 Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin Hara, M. Yamagata, K. Tomino, Y. Saito, A. Hirayama, Y. Ogasawara, S. Kurosawa, H. Sekine, S. Yan, K. Diabetologia Article AIMS/OBJECTIVE: Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Recent studies have demonstrated that podocyte injury is involved in the onset of and progression to renal insufficiency. Here, we describe a novel, highly sensitive ELISA for detecting urinary podocalyxin, a glycoconjugate on the podocyte apical surface that indicates podocyte injury, particularly in the early phase of diabetic nephropathy. METHODS: Urine samples from patients with glomerular diseases (n = 142) and type 2 diabetes (n = 71) were used to quantify urinary podocalyxin by ELISA. Urine samples were obtained from 69 healthy controls for whom laboratory data were within normal values. Podocalyxin was detected in urine by immunofluorescence, immunoelectron microscopy and western blotting. RESULTS: Morphologically, urinary podocalyxin was present as a vesicular structure; western blotting showed it as a positive band at 165–170 kDa. Levels of urinary podocalyxin were elevated in patients with various glomerular diseases and patients with diabetes. In patients with diabetes, urinary podocalyxin was higher than the cut-off value in 53.8% patients at the normoalbuminuric stage, 64.7% at the microalbuminuric stage and 66.7% at the macroalbuminuric stage. Positive correlations were observed between urinary podocalyxin levels and HbA(1c), urinary β(2) microglobulin, α(1) microglobulin and urinary N-acetyl-β-d-glucosaminidase, although urinary podocalyxin levels were not correlated with other laboratory markers such as blood pressure, lipid level, serum creatinine, estimated GFR or proteinuria. CONCLUSIONS/INTERPRETATION: Urinary podocalyxin may be a useful biomarker for detecting early podocyte injury in patients with diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-012-2661-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer-Verlag 2012-08-02 2012 /pmc/articles/PMC3464371/ /pubmed/22854890 http://dx.doi.org/10.1007/s00125-012-2661-7 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Article
Hara, M.
Yamagata, K.
Tomino, Y.
Saito, A.
Hirayama, Y.
Ogasawara, S.
Kurosawa, H.
Sekine, S.
Yan, K.
Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin
title Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin
title_full Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin
title_fullStr Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin
title_full_unstemmed Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin
title_short Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin
title_sort urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive elisa to detect urinary podocalyxin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464371/
https://www.ncbi.nlm.nih.gov/pubmed/22854890
http://dx.doi.org/10.1007/s00125-012-2661-7
work_keys_str_mv AT haram urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin
AT yamagatak urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin
AT tominoy urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin
AT saitoa urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin
AT hirayamay urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin
AT ogasawaras urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin
AT kurosawah urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin
AT sekines urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin
AT yank urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin